AMENDMENTS TO THE CLAIMS:

Please amend the claims as follows:

Claims 1-22. (Canceled)

23. (Currently Amended) A method for the treatment of Charcot-Marie-Tooth disease comprising administering to a subject affected by or presenting a risk of developing such disease, an effective amount of vitamin C or a derivative thereof selected from the group consisting of: ascorbic acid, ascorbyl palmitate, dipalmitate L-ascorbate, glycosylated, mannosylated, fructosylated, fucosylated, galactosylated, N-acetylglucosaminated, N-acetylmuramic derivatives of ascorbic acid, the metal salts of phosphorylated ascorbic acid, the alkaline metal ascorbyl phosphates, the alkaline earth metal ascorbyl phosphates, the transition metal ascorbyl phosphates, the ascorbyl sulphates, ascorbyl-2 glucoside, 2-O-alpha-D-glucopyranosyl ascorbic acid, 6-O-beta-D-galactopyranosyl L-ascorbic acid, and magnesium ascorbyl phosphate.

Claims 24-28. (Canceled)

29. (Previously Presented) The method according to claim 23, wherein said Charcot-Marie-Tooth disease is type I Charcot-MarieTooth disease (CMTI).

Claim 30. (Canceled)

31. (Previously Presented) The method according to claim 23, wherein the vitamin C is selected from the group consisting of natural vitamin C, synthetic vitamin C and a mixture thereof.

Claims 32-34. (Canceled)

Claims 35-44. (Canceled)

Claim 45. (Cancelled)

Claim 46. (Cancelled)

47. (Currently Amended) The method according to claim 23, wherein the vitamin C or [[a]]the derivative thereof ~~selected in the group consisting of vitamin C salts and esters~~ is used as the therapeutically active ingredient.

48. (Previously Presented) The method according to claim 23, wherein the vitamin C or a derivative thereof is administered to a human in need of such treatment in unit doses comprising from 1 g to 6 grams of vitamin C or a derivative thereof.

Claim 49. (Canceled)

Claim 50. (Canceled)